Related Experiment Video
Updated: May 17, 2026

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
Clinical potential of VIP by modified pharmaco-kinetics and delivery mechanisms
Bernhard Burian1, Anna Ortner, Ruth Prassl
1Medical University Vienna, Internal Medicine-II, Pneumology, Vienna, Austria.
Abstract:
Vasoactive intestinal peptide (VIP) conveys various physiological effects in the digestive tract, nervous and cardiovascular system, airways, reproductive system, endocrine system, and more. A family of specific membrane bound receptors, termed VPAC1, VPAC2, and PAC1, bind VIP and trigger the effects. Many of them are of clinical interest. To date more than two thousand publications suggest the use of VIP in diseases like asthma, erectile dysfunction, blood pressure regulation, inflammation, endocrinology, tumours, etc. Despite this considerable potential, the peptide is not regularly used in clinical settings. A key problem is the short half life of inhaled or systemically administered VIP due to rapid enzymatic degradation. This shortcomings could be overcome with stable derivates or improved pharmacokinetics. A promising strategy is to use biocompatible and degradable depots, to protect the peptide from early degradation and allow for controlled release. This review focuses on aspects of clinical applications of VIP and the idea to use formulations based on biodegradable particles, to constitute a dispersible VIP-depot. Smart particle systems protect the peptide from early degradation, and assist the sustainable cell targeting with VIP for therapeutic or imaging purposes.
Related Concept Videos
Modified-Release Drug Delivery Systems: Site-Targeted
Biopharmaceutics and Pharmacokinetics: Overview
Modified-Release Drug Delivery Systems: Influencing Factors
Modified-Release Drug Delivery Systems: Bioavailability
Drug Product Performance: In Vitro–In Vivo Correlation
Modified-Release Drug Delivery Systems: Overview
